LIVN (LivaNova PLC) Stock Financials & Earnings

LIVNLivaNova PLC

Mkt Cap$3B

Healthcare·Medical - Devices·🇬🇧 United Kingdom·NASDAQ

Revenue (TTM)$1.4B

Net Income (TTM)-$242M

EPS (TTM)-$4.45

Free Cash Flow (TTM)$173M

Gross Margin68.0%

Op. Margin14.4%

Net Margin-17.5%

FCF Margin12.5%

P/S Ratio (TTM)2.4x

P/E Ratio (TTM)—

YoY Rev Growth+10.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$263M	$174M	-$2M
Q2 23	$294M	$205M	$17M
Q3 23	$286M	$202M	$4M
Q4 23	$310M	$190M	-$88M
Q1 24	$295M	$207M	$16M
Q2 24	$319M	$215M	$40M
Q3 24	$318M	$225M	$36M
Q4 24	$322M	$219M	$37M
Q1 25	$317M	$221M	$49M
Q2 25	$353M	$239M	$54M
Q3 25	$358M	$245M	$54M
Q4 25	$361M	$240M	$43M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Advanced Circulatory Support Segment	Cardiopulmonary Segment	Neuromodulation Segment
Q1 23	$10M	$132M	$121M
Q2 23	$9M	$151M	$133M
Q3 23	$11M	$145M	$129M
Q4 23	$10M	$161M	$137M
Q1 24	—	$156M	$134M
Q2 24	—	$174M	$143M
Q3 24	—	$172M	$140M
Q4 24	—	$182M	$138M
Q1 25	—	$176M	$139M
Q2 25	—	$199M	$152M
Q3 25	—	$203M	$150M
Q4 25	—	$207M	$153M

Revenue by Geography

Quarter	Europe	Locations Excluding The United States And Europe	United States
Q1 23	$50M	$74M	$140M
Q2 23	$54M	$79M	$160M
Q3 23	$48M	$76M	$162M
Q4 23	$63M	$74M	$173M
Q1 24	$54M	$80M	$161M
Q2 24	$51M	$88M	$180M
Q3 24	$53M	$85M	$180M
Q4 24	$62M	$85M	$175M
Q1 25	$60M	$88M	$169M
Q2 25	$67M	$97M	$188M
Q3 25	$68M	$100M	$190M
Q4 25	$75M	$94M	$191M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$523M	$0	$523M
Q2 23	$534M	$0	$534M
Q3 23	$234M	$0	$234M
Q4 23	$267M	$0	$267M
Q1 24	$309M	$0	$309M
Q2 24	$329M	$0	$329M
Q3 24	$346M	$0	$346M
Q4 24	$429M	$0	$429M
Q1 25	$738M	$0	$738M
Q2 25	$594M	$0	$594M
Q3 25	$646M	$0	$646M
Q4 25	$636M	$0	$636M

Shares Outstanding

Revenue Per Employee

Revenue / Employee